We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

The Efficacy and Safety of Intraarticular Sodium Hyaluronate (Hyalgan) After Proximal Tibial Osteotomy in Treatment of Knee Osteoarthritis Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01267214
Recruitment Status : Completed
First Posted : December 28, 2010
Last Update Posted : November 21, 2012
Information provided by (Responsible Party):
TRB Chemedica

Brief Summary:
The purpose of this study is to assess the efficacy and safety of Hyalgan after proximal tibial osteotomy in treatment of knee osteoarthritis patients. Normally, OA patients who were treated with osteotomy will not be treated with any SYSADOA after operation, even though their cartilage's not completely loss, so osteotomy plus HA injection should provide more benefit to patients than osteotomy alone.

Condition or disease Intervention/treatment Phase
Knee Osteoarthritis Drug: Sodium Hyaluronate (Hyalgan) Procedure: Osteotomy alone Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Study Start Date : February 2009
Primary Completion Date : February 2010
Study Completion Date : July 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Osteotomy plus Hyalgan
Osteotomy at Week 0 Hyalgan injection at Week 2, 3, 4, 5, 6, 24, 25, 26, 27, 28
Drug: Sodium Hyaluronate (Hyalgan)
1% Sodium Hyaluronate in prefilled syringe
Osteotomy alone Procedure: Osteotomy alone
no injection

Primary Outcome Measures :
  1. Joint Space Width [ Time Frame: 12 months ]
  2. Global assessment [ Time Frame: 12 months ]
    assess by Patient and investigator

  3. WOMAC section A, B, C [ Time Frame: 12 months ]
    Pain score

  4. Rescue medicine consumption [ Time Frame: 12 months ]
    Diclofenac consumption

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   35 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients between 35 and 65 years with primary knee OA with malalignment
  2. Mild to moderate OA of grade II or III severity on the Kellgren-Lawrence scale with require treatment by osteotomy
  3. Malalignment is not exceed 15 degree (+,-)
  4. Pain on walking (15 m) ≥ 40 mm.
  5. Range of motion > 90 degree
  6. Evidence of adequate contraceptive methods in women of childbearing age

Exclusion Criteria:

  1. Previous surgery on affected knee
  2. Previous intraarticular intervention within the last 3 months (eg. Steroid, anaesthetic, Sodium hyaluronate)
  3. Oral SYSADOA treatment (chondroitin, glucosamine, diacerein) within 2 months prior to study start
  4. Known or suspected infection of the affected joint
  5. Painful knee condition due to another cause than chondral lesions, such as Sudeck's atrophy, intraarticular neoplasm, pigmented villonodular synovitis, chondromatosis
  6. Poor general health or other conditions which would make regular hospital attendance difficult
  7. Ascertained hypersensitivity to any component used in the study (eg. Hyaluronic acid, diclofenac, morphine, omeprazole and paracetamol)
  8. Hypersensitivity to avian protein
  9. Ongoing or previous participation in a clinical study within the last 3 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01267214

Siriraj Hospital, Faculty of Medicine, Mahidol university
Bangkok, Thailand, 10700
Sponsors and Collaborators
TRB Chemedica

Responsible Party: TRB Chemedica
ClinicalTrials.gov Identifier: NCT01267214     History of Changes
Other Study ID Numbers: HGN-THA-08-01
First Posted: December 28, 2010    Key Record Dates
Last Update Posted: November 21, 2012
Last Verified: November 2012

Additional relevant MeSH terms:
Osteoarthritis, Knee
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Hyaluronic Acid
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Protective Agents